New long-term results validate roflumilast cream 0.15% efficacy in atopic dermatitis

Roflumilast cream 0.15% demonstrated long-term efficacy and tolerability in adults and children aged 6 years and older with atopic dermatitis, Arcutis announced in a press release.
These new 56-week results from Arcutis’ long term, open-label INTEGUMENT-OLE study were presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference.
“A major challenge for managing atopic dermatitis patients is the ability to keep their disease controlled over a long-term period,” Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis, told Healio. “The results

Roflumilast cream 0.15% demonstrated long-term efficacy and tolerability in adults and children aged 6 years and older with atopic dermatitis, Arcutis announced in a press release.
These new 56-week results from Arcutis’ long term, open-label INTEGUMENT-OLE study were presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference.
“A major challenge for managing atopic dermatitis patients is the ability to keep their disease controlled over a long-term period,” Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis, told Healio. “The results